DNDi Utilizing Pinnacle 21 Enterprise (P21E), Certara’s Data Science platform for Biostatistics, Data Management, and Data Standards to Streamline Clinical Data Flow PRINCETON, NJ/NAIROBI, KE, July 31, 2023 – Certara,…
What is model-informed drug development (MIDD), and why is it so critical to informing the development of safer and more effective new drugs? During this event, you will uncover ways…
You are having a good day as a quality assurance professional at a small pharmaceutical company until you open an email from your company president asking for an explanation. She…
Latest updates demonstrate commitment to customers and market leadership of Phoenix Platform PRINCETON, N.J.— June 12, 2023. Certara®, the global leader in biosimulation, today announced the launch of version 8.4…
Access to safe and effective medications is critical for pediatric patients, yet 60-70% of medicines prescribed to children are off-label. In Japan, only 30% of new drugs are approved for…
Tailored biometrics capabilities that cover the full drug development continuum (pre-clinical through NDA/BLA).
Tap into knowledge of our experts who have thousands of years of combined experience across drug development.
Accelerate drug development with customized biosimulation to predict efficacy, safety, and optimal dosing strategies.
© 2025 Certara. All Rights Reserved. | Privacy policy
